RESEARCH

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over five years: supplementary material

Adam R Brentnall¹, Ruth Warren², Elaine F Harkness^{3,4}, Susan M Astley^{3,4,5}, Julia Wiseman⁴, Jill Fox⁴, Lynne Fox⁴, Mikael Eriksson⁶, Per Hall⁶, Jack Cuzick¹, D Gareth Evans^{4,7,8,5} and Anthony Howell^{4,5,9*}

*Correspondence: ⁴Manchester University NHS Foundation Trust, Prevent Breast Cancer Centre, Wythenshawe Hospital M23 9LT Manchester, UK Full list of author information is available at the end of the article

Eligibility criteria for TAM-PREV

To be eligible women were required to be: aged 33-46y; premenopausal; attending the Family History Clinic at the Nightingale & Genesis Prevention Centre, Manchester UK; and at moderate or high-risk as defined by a Tyrer-Cuzick lifetime risk of >17% (version 7, [1, 2]) as per the UK national institute of clinical excellence guidelines [3]. They also had to have a negative pregnancy test; be willing to use a non-hormonal form of contraception (Mirena coil was acceptable) and a normal mammogram no more than 12 weeks prior to joining the study. Women were ineligible if: any previous cancer in the past 5 years (except basal cell carcinoma or in situ cancer of the cervix); current or previous tamoxifen or raloxifene or other Selective Oestrogen Receptor Modulators use for more than 3 months prior to participation in study; had a prophylactic mastectomy or are planning to have this procedure; pregnancy or breastfeeding; use of hormonal contraceptives for the last 3 months (Oral Contraceptive Pill, Depo provera and Implanon/Nexplanon, Mirena coil was permitted). Women were not eligible if they had a bilateral oophorectomy; hypersensitivity to tamoxifen or any of its ingredients; personal or close family history of thromboembolism (defined as at least 2 affected relatives with 1 being a 1st degree relative); were using coumarin type anticoagulants, droperidol or bupropion; had Type 1 or 2 diabetes or symptomatic gynaecological problems requiring medication.


Author details

¹Queen Mary University of London, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Charterhouse square, EC1M 6BQ London, UK. ²Department of Radiology, University of Cambridge, Addenbrooke's Hospital Cambridge, UK. ³University of Manchester, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health Manchester, UK. ⁴Manchester University NHS Foundation Trust, Prevent Breast Cancer Centre, Wythenshawe Hospital M23 9LT Manchester, UK. ⁵University of Manchester, Manchester Breast Centre, Manchester Cancer Research Centre M20 4BX Manchester, UK. ⁶Karolinska Institutet,Department of Medical Epidemiology and Biostatistics Stockholm, Sweden. ⁷Manchester University NHS Foundation Trust, NW Genomic Laboratory Hub, Manchester Centre for Genomic Medicine M13 9WL Manchester, UK. ⁸University of Manchester, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Manchester, Division of Cancer Sciences, Faculty of Biology, Medicine and Health M13 9PL Manchester, UK.

References

- 1. Tyrer, J., Duffy, S.W., Cuzick, J.: A breast cancer prediction model incorporating familial and personal risk factors. Statistics in medicine 23(7), 1111–1130 (2004). doi:10.1002/sim.1668
- Brentnall, A.R., Cuzick, J.: Risk Models for Breast Cancer and Their Validation. Statistical Science 35(1), 14–30 (2020). doi:10.1214/19-STS729
- Evans, D.G., Brentnall, A.R., Harvie, M., Dawe, S., Sergeant, J.C., Stavrinos, P., Astley, S., Wilson, M., Ainsworth, J., Cuzick, J., Buchan, I., Donnelly, L.S., Howell, A.: Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. Cancer Prevention Research 7(10), 993–1001 (2014). doi:10.1158/1940-6207.capr-14-0037

Supplementary material



 $\label{eq:stable} \begin{array}{l} \textbf{Table S1} \\ \textbf{Baseline characteristics of participants in analysis sample A (all women included in the study). \end{array}$

		Tamoxifen	No tamoxifen		
	N (% unknown)	Summary*	N (% unknown)	Summary*	
Age (y)	126 (0%)	42 (39-45, 33-47)	172 (0%)	41 (39-44, 31-47)	
BMI (kg/m^2)	126 (0%)	25.8 (22.0-29.8, 18.0-51.0)	145 (16%)	24.9 (22.3-29.9, 17.9-48.0)	
Lifetime risk (%)	126 (0%)	33.3 (27.1-33.3, 17.0-80.0)	172 (0%)	33.3 (25.0-33.3, 14.0-80.0)	
Parous (n, %)	126 (0%)	103 (82%)	172 (0%)	132 (77%)	
Age first born (y)	95 (25%)	27.0 (22.0-32.0, 17.0-42.0)	132 (23%)	27.0 (21.0-31.0, 15.0-40.0)	

* summary gives median (interquartile range, range) for continuous variables and n (%) for parous.

Table S2 Baseline characteristics of participants in analysis sample B (women with 1y density change)
measured). Footnote: *summary gives median (interquartile range, range) for continuous variables
and n (%) for parous; TP: Tamoxifen; FH: No Tamoxifen

		Tamoxifen	N	No tamoxifen		
	N (% unknown)	Summary*	N (% unknown)	Summary*		
Age (y)	94 (0%)	43 (40-45, 33-47)	112 (0%)	40 (38-44, 31-47)		
BMI (kg/m^2)	94 (0%)	26.0 (22.0-29.8, 18.0-46.0)	95 (15%)	24.9 (22.2-30.0, 19.2-41.2)		
TC lifetime? (%)	94 (0%)	33.3 (33.3-33.3, 17.0-80.0)	112 (0%)	33.3 (25.0-33.3, 14.0-80.0)		
Parous (n, %)	94 (0%)	71 (76%)	112 (0%)	88 (79%)		
Age first child (y)	67 (29%)	27.0 (22.5-33.0, 18.0-39.0)	88 (21%)	26.0 (20.8-30.2, 15.0-40.0)		

* summary gives median (interquartile range, range) for continuous variables and n (%) for parous.

Table S3 Baseline characteristics of participants excluded from analysis sample B (women with 1y density change measured). Footnote: *summary gives median (interquartile range, range) for continuous variables and n (%) for parous; TP: Tamoxifen; FH: No Tamoxifen

		Tamoxifen	No tamoxifen					
	N (% unknown)	Summary*	N (% unknown)	Summary*				
Age (y)	32 (0%)	42 (38-44, 34-46)	60 (0%)	42 (40-44, 34-46)				
BMI (kg/m^2)	32 (0%)	25.0 (22.0-29.2, 18.7-51.0)	50 (17%)	24.6 (22.7-28.8, 17.9-48.0)				
TC lifetime? (%)	32 (0%)	33.3 (25.0-40.0, 17.0-50.0)	60 (0%)	33.3 (25.0-33.3, 15.0-50.0)				
Parous (n, %)	32 (0%)	32 (100%)	60 (0%)	44 (73%)				
Age first child (y)	28 (12%)	26.0 (22.0-31.2, 17.0-42.0)	44 (27%)	27.0 (22.0-31.0, 16.0-39.0)				
* summary gives me	* summary gives median (interquartile range, range) for continuous variables and n (%) for parous.							

Table S4 Baseline characteristics of participants in analysis sample C (women with 1y and 2y density change measured). Footnote: *summary gives median (interquartile range, range) for continuous variables and n (%) for parous; TP: Tamoxifen; FH: No Tamoxifen

		Tamoxifen	No tamoxifen		
	N (% unknown)	Summary*	N (% unknown)	Summary*	
Age (y)	70 (0%)	43 (40-44, 33-47)	89 (0%)	40 (38-44, 31-47)	
BMI (kg/m^2)	70 (0%)	26.0 (22.2-29.0, 18.0-46.0)	76 (15%)	26.1 (22.6-30.0, 19.2-41.2)	
TC lifetime? (%)	70 (0%)	33.3 (27.1-33.3, 17.0-50.0)	89 (0%)	33.3 (25.0-33.3, 14.0-80.0)	
Parous (n, %)	70 (0%)	54 (77%)	89 (0%)	74 (83%)	
Age first child (y)	50 (29%)	28.0 (23.0-33.0, 19.0-37.0)	74 (17%)	27.5 (21.0-31.0, 15.0-40.0)	
*	dian (interruprtile r	ange range) for continuous varial	aloc and n (9/) for nor		

 st summary gives median (interquartile range, range) for continuous variables and n (%) for parous.

Table S5 Baseline characteristics of participants excluded from analysis sample C (women with 1y and 2y density change), out of all women included in the study (analysis sample A). Footnote: *summary gives median (interquartile range, range) for continuous variables and n (%) for parous; TP: Tamoxifen; FH: No Tamoxifen

		Tamoxifen	No tamoxifen					
	N (% unknown)	Summary*	N (% unknown)	Summary*				
Age (y)	56 (0%)	42 (38-45, 33-46)	83 (0%)	42 (39-44, 32-47)				
BMI (kg/m^2)	56 (0%)	25.0 (22.0-33.2, 18.7-51.0)	69 (17%)	24.0 (21.9-29.2, 17.9-48.0)				
TC lifetime? (%)	56 (0%)	33.3 (31.2-40.0, 17.0-80.0)	83 (0%)	33.3 (33.3-33.3, 15.0-80.0)				
Parous (n, %)	56 (0%)	49 (88%)	83 (0%)	58 (70%)				
Age first child (y)	45 (20%)	26.0 (22.0-32.0, 17.0-42.0)	58 (30%)	26.5 (21.2-30.0, 16.0-39.0)				
* summary gives me	* summary gives median (interquartile range, range) for continuous variables and n (%) for parous.							

summary gives median (interquartie range, range) for continuous variables and in (70) for parous.

Table S6 Repeated measures correlation (between women) between density measures for tamoxifen group, analysis sample A (all women included in the study).

	Visual %	Visual (unblind) %	Stratus %	Densitas %	Volpara %	Stratus DA	Densitas DA	Volpara DV	Densitas BA	Volpara TV
Visual (unblind) %	0.94									
Stratus %	0.87	0.80								
Densitas %	0.88	0.85	0.92							
Volpara %	0.89	0.85	0.91	0.91						
Stratus DA	0.73	0.69	0.89	0.82	0.71					
Densitas DA	0.20	0.23	0.24	0.30	0.07	0.61				
Volpara DV	0.48	0.53	0.47	0.54	0.40	0.72	0.84			
Densitas BA	-0.42	-0.37	-0.44	-0.43	-0.57	-0.05	0.72	0.42		
Volpara TV	-0.50	-0.42	-0.53	-0.48	-0.68	-0.13	0.60	0.40	0.91	
NNVAS %	0.89	0.84	0.94	0.93	0.91	0.88	0.35	0.59	-0.34	-0.43

DA: dense area; DV: dense volume; BA: breast area; TV total volume

Table S7 Linear mixed model fit, main effect estimates (95%CI)

	Intercept	Age	BMI	Tamoxifen	Year 1	Time (year 2+)	(Year 1):(Tamoxifen)	(Time, year 2+):
		(5y)	(5kg/m ²)	(Y=1, N=0)	(Y=1, N=0)	(y)	interaction	(Tamoxifen) interaction
Volpara %	9.0 (1.8 to 16.3)	-7.2 (-43.8 to 29.3)	-33.7 (-38.5 to -28.9)	7.0 (-3.8 to 17.9)	-3.1 (-4.4 to -1.8)	1.0 (-1.7 to 3.6)	-17.1 (-21.4 to -12.8)	-6.2 (-8.2 to -4.2)
Stratus %	7.8 (1.0 to 14.5)	-14.4 (-47.3 to 18.6)	-26.8 (-31.2 to -22.3)	3.4 (-6.7 to 13.5)	-1.3 (-2.4 to -0.1)	0.2 (-2.1 to 2.5)	-18.0 (-21.8 to -14.3)	-2.3 (-4.2 to -0.5)
Densitas %D	11.8 (2.2 to 21.3)	2.4 (-45.7 to 50.4)	-34.7 (-41.0 to -28.3)	5.0 (-9.4 to 19.3)	-1.9 (-3.9 to 0.0)	-1.2 (-5.5 to 3.1)	-24.9 (-31.8 to -17.9)	-6.9 (-10.0 to -3.9)
NNVAS %	7.2 (-2.1 to 16.4)	-15.3 (-61.0 to 30.5)	-28.3 (-34.4 to -22.2)	4.0 (-9.8 to 17.9)	-0.1 (-1.5 to 1.3)	-0.8 (-4.0 to 2.4)	-21.7 (-26.9 to -16.5)	-5.0 (-7.2 to -2.7)
Volpara DV	3.0 (-7.3 to 13.2)	4.8 (-45.3 to 54.9)	7.7 (1.1 to 14.4)	-6.2 (-21.7 to 9.2)	2.4 (0.5 to 4.2)	-6.3 (-10.4 to -2.2)	-22.8 (-29.5 to -16.2)	-6.0 (-8.8 to -3.1)
Stratus DA	6.2 (-3.9 to 16.3)	-14.4 (-62.8 to 34.0)	-17.7 (-24.1 to -11.2)	0.8 (-14.3 to 16.0)	-0.9 (-2.4 to 0.7)	0.1 (-3.1 to 3.2)	-27.3 (-32.4 to -22.2)	-2.6 (-5.1 to -0.1)
Densitas DA	-1.8 (-12.7 to 9.0)	22.1 (-31.9 to 76.1)	24.1 (16.9 to 31.3)	-8.8 (-25.1 to 7.6)	0.0 (-1.9 to 1.9)	0.3 (-4.0 to 4.6)	-25.7 (-32.7 to -18.7)	-4.6 (-7.7 to -1.6)
DA: dense area	a; DV: dense volume							

Table S8 Linear mixed model fit estimated variance components (95%CI).							
	Intercept	Time (y)	Intercept:Time	(correlation)	Residual		
Volpara %	47.1 (43.5 to 51.2)	4.3 (3.5 to 5.1)	-0.1 (-0.3 to 0.1)	14.1 (13.4 to 14.9)		

	Intercept	Time (y)	Intercept:Time (correlation)	Residual	ICC
Volpara %	47.1 (43.5 to 51.2)	4.3 (3.5 to 5.1)	-0.1 (-0.3 to 0.1)	14.1 (13.4 to 14.9)	0.92 (0.90 to 0.93)
Stratus %	44.0 (40.7 to 47.8)	4.1 (3.4 to 4.9)	-0.3 (-0.4 to -0.1)	12.2 (11.6 to 12.8)	0.93 (0.90 to 0.94)
Densitas %	61.0 (56.2 to 66.5)	5.2 (3.9 to 6.5)	0.0 (-0.2 to 0.3)	23.3 (22.2 to 24.5)	0.87 (0.83 to 0.90)
NNVAS %	60.2 (55.7 to 65.4)	3.8 (2.7 to 4.8)	-0.3 (-0.5 to -0.1)	17.4 (16.6 to 18.4)	0.92 (0.90 to 0.93)
Volpara DV	66.5 (61.4 to 72.2)	5.1 (3.8 to 6.3)	-0.3 (-0.5 to -0.1)	22.3 (21.2 to 23.4)	0.90 (0.87 to 0.91)
Stratus DA	66.4 (61.4 to 72.0)	5.7 (4.7 to 6.7)	-0.4 (-0.5 to -0.2)	16.8 (15.9 to 17.6)	0.94 (0.91 to 0.95)
Densitas DA	70.4 (65.0 to 76.5)	5.2 (3.8 to 6.5)	-0.1 (-0.3 to 0.1)	23.4 (22.3 to 24.6)	0.90 (0.85 to 0.93)

DA: dense area; DV: dense volume; ICC: intra-class correlation coeficient; CI: confidence interval

Table S9 Linear model fit, fixed effects (95%CI), tamoxiden group only.

	Intercept	Age (5y)	BMI (5kg/m ²)	Year 1	Time (year 2+)
Volpara %	14.4 (5.0 to 23.6)	18.4 (-40.6 to 77.4)	-27.9 (-34.6 to -21.2)	-7.0 (-10.9 to -3.0)	-9.3 (-10.9 to -7.6)
Stratus %	9.0 (0.5 to 17.5)	0.9 (-52.5 to 54.4)	-20.6 (-26.7 to -14.6)	-14.2 (-17.9 to -10.6)	-3.7 (-5.0 to -2.3)
Densitas %	15.6 (2.8 to 28.2)	37.4 (-45.4 to 120.2)	-29.1 (-38.1 to -20.0)	-17.3 (-24.0 to -10.6)	-8.9 (-11.3 to -6.4)
NNVAS %	8.9 (-3.1 to 20.7)	6.2 (-67.9 to 80.3)	-21.4 (-29.7 to -13.1)	-17.4 (-22.4 to -12.5)	-5.1 (-6.7 to -3.4)
Volpara DV	-3.0 (-15.2 to 9.3)	56.3 (-18.3 to 130.7)	11.2 (3.0 to 19.4)	-25.6 (-31.0 to -20.2)	-3.6 (-5.6 to -1.6)
Stratus DA	5.3 (-6.9 to 17.4)	9.3 (-64.1 to 82.7)	-11.7 (-19.8 to -3.5)	-23.8 (-28.5 to -19.2)	-3.5 (-5.2 to -1.7)
Densitas DA	-9.9 (-22.6 to 2.9)	33.5 (-46.1 to 113.3)	23.3 (14.1 to 32.5)	-20.9 (-27.6 to -14.1)	-4.7 (-7.0 to -2.4)
DA: dense are	a; DV: dense volume	· · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · ·	

Table S10 Linear mixed model fit estimated variance components (95%CI), tamoxifen group only.

	Intercept	Time (y)	Intercept:Time (correlation)	Residual
Volpara %	47.9 (42.3 to 54.6)	4.8 (3.6 to 6.2)	-0.3 (-0.6 to 0.0)	13.6 (12.6 to 14.7)
Stratus %	44.0 (38.9 to 50.3)	3.5 (2.4 to 4.7)	-0.4 (-0.6 to 0.0)	12.7 (11.8 to 13.8)
Densitas %	64.5 (56.8 to 73.8)	5.4 (3.2 to 7.6)	0.0 (-0.3 to 0.4)	23.4 (21.7 to 25.4)
NNVAS %	61.9 (54.7 to 70.6)	3.4 (1.3 to 5.2)	-0.5 (-1.0 to -0.1)	17.2 (15.9 to 18.7)
Volpara DV	63.5 (56.1 to 72.5)	5.0 (3.4 to 6.8)	-0.6 (-0.8 to -0.3)	18.8 (17.5 to 20.4)
Stratus DA	63.8 (56.5 to 72.7)	4.9 (3.5 to 6.5)	-0.6 (-0.8 to -0.3)	16.1 (14.9 to 17.4)
Densitas DA	64.6 (56.8 to 74.0)	4.6 (2.1 to 6.9)	-0.4 (-0.7 to 0.1)	23.7 (21.9 to 25.7)
DA. damas and	a DV/ dance velume			

DA: dense area; DV: dense volume

Table S11 Number of women and total number of measures that agree on breast density measure change (Volpara %, Stratus %, Densitas %, NNVAS %) above cutpoint at year 1 (T0) or year 2 (T2) compared with baseline (T0).

	No change	Only one	Two	Three	All agree	Total number		
	by any measure	measure	measures	measures	on change	women		
1y change (T0 - T1)	6 (9%)	17 (24%)	12 (17%)	16 (23%)	19 (27%)	70 (100%)		
2y change (T0 - T2)	8 (11%)	8 (11%)	13 (19%)	19 (27%)	22 (31%)	70 (100%)		
T0: entry; T1: follow-up at 1y; T2: follow-up at 2y.								

Table S12 Agreement in density change between pairs of density measures (n=70 in total from tamoxifen group, analysis sample (C)). (a) compares between baseline (T0) and first followup at one year (T1); (b) compares change between baseline and two years later (T2); and (c) considers the concordance between change measured at one year (T0 - T1) and two years (T0 - T2), including for the same measure of breast density.

Comparison	Stratus %	Densitas %	Volpara %	NNVAS %
(a) T1 - T0				
Śtratus %		28/60 (47%)	29/54 (54%)	30/52 (58%)
Densitas %		, , ,	31/52 (60%)	28/54 (52%)
Volpara %			,	28/49 (57%)
(b) T2 - T0				
Stratus %		29/58 (50%)	36/57 (63%)	39/54 (72%)
Densitas %			31/55 (56%)	31/55 (56%)
Volpara %				36/56 (64%)
(c) (T1 - T0) vs (T2 - T0)				
Stratus %	36/55 (65%)	25/59 (42%)	32/58 (55%)	32/58 (55%)
Densitas %		33/51 (65%)	32/58 (55%)	32/58 (55%)
Volpara %			31/54 (57%)	31/54 (57%)
NNVAS %				32/52 (62%)